

Antonio Salar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4622887/publications.pdf>

Version: 2024-02-01

98
papers

2,845
citations

185998

28
h-index

197535

49
g-index

100
all docs

100
docs citations

100
times ranked

3744
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of Leptomeningeal Disease in Aggressive B-Cell Non-Hodgkin's Lymphoma: Improved Sensitivity of Flow Cytometry. <i>Journal of Clinical Oncology</i> , 2009, 27, 1462-1469.	0.8	189
2	Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. <i>Blood</i> , 2010, 116, 1479-1488.	0.6	174
3	R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. <i>Haematologica</i> , 2008, 93, 1829-1836.	1.7	158
4	Gastrointestinal Involvement in Mantle Cell Lymphoma: A Prospective Clinic, Endoscopic, and Pathologic Study. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1274-1280.	2.1	121
5	Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. <i>Haematologica</i> , 2007, 92, 1489-1494.	1.7	116
6	A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. <i>Blood</i> , 2018, 132, 413-422.	0.6	89
7	Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1782-1791.	0.8	84
8	Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. <i>British Journal of Haematology</i> , 2012, 159, 164-171.	1.2	81
9	Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. <i>Cancer</i> , 2009, 115, 5210-5217.	2.0	78
10	First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2014, 1, e104-e111.	2.2	77
11	Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 10534-10539.	3.3	73
12	Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. <i>Haematologica</i> , 2014, 99, 1228-1235.	1.7	69
13	Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 439-451.	1.5	68
14	Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of I^2 microglobulin yields a more accurate GELTAMO-IPI. <i>British Journal of Haematology</i> , 2017, 176, 918-928.	1.2	65
15	Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. <i>Blood</i> , 2017, 130, 1772-1774.	0.6	60
16	Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients. <i>British Journal of Haematology</i> , 2009, 146, 504-509.	1.2	50
17	Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era. <i>European Journal of Haematology</i> , 2010, 85, 321-328.	1.1	49
18	A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. <i>Blood</i> , 2010, 116, e12-e17.	0.6	47

#	ARTICLE	IF	CITATIONS
19	Distinction between Asymptomatic Monoclonal B-cell Lymphocytosis with Cyclin D1 Overexpression and Mantle Cell Lymphoma: From Molecular Profiling to Flow Cytometry. <i>Clinical Cancer Research</i> , 2014, 20, 1007-1019.	3.2	44
20	Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution. <i>European Journal of Haematology</i> , 2006, 77, 338-340.	1.1	43
21	Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics. <i>Nature Communications</i> , 2016, 7, 11889.	5.8	42
22	Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation in Metallic Implant. <i>Journal of Clinical Oncology</i> , 2013, 31, e148-e151.	0.8	41
23	Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. <i>Leukemia and Lymphoma</i> , 2014, 55, 929-931.	0.6	40
24	Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO). <i>Haematologica</i> , 2017, 102, 235-245.	1.7	40
25	New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta α 2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO). <i>British Journal of Haematology</i> , 2020, 188, 888-897.	1.2	40
26	The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: Findings from clinical practice. <i>Leukemia Research</i> , 2012, 36, 548-553.	0.4	35
27	Study of Regulatory T-Cells in Patients with Gastric Malt Lymphoma: Influence on Treatment Response and Outcome. <i>PLoS ONE</i> , 2012, 7, e51681.	1.1	35
28	Linfoma MALT gástrico y Helicobacter pylori. <i>Medicina Clínica</i> , 2019, 152, 65-71.	0.3	34
29	Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome. <i>Blood</i> , 2014, 123, 1864-1869.	0.6	30
30	NT-proBNP: A cardiac biomarker to assess prognosis in non-Hodgkin lymphoma. <i>Leukemia Research</i> , 2011, 35, 715-720.	0.4	29
31	Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogeneously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment. <i>Nuclear Medicine Communications</i> , 2013, 34, 946-952.	0.5	27
32	Double Diagnosis in Cancer Patients and Cutaneous Reaction Related to Gemcitabine. <i>Journal of Clinical Oncology</i> , 2005, 23, 7221-7223.	0.8	26
33	Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. <i>Nature Communications</i> , 2021, 12, 5183.	5.8	26
34	Primary cutaneous diffuse large B-cell lymphoma, leg type and secondary cutaneous involvement by testicular B-cell lymphoma share identical clinicopathological and immunophenotypical features. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 650-654.	0.6	25
35	First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group. <i>Haematologica</i> , 2013, 98, 1563-1570.	1.7	25
36	Lenalidomide in combination with ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group. <i>British Journal of Haematology</i> , 2016, 173, 245-252.	1.2	24

#	ARTICLE	IF	CITATIONS
37	Persistent Residual Disease in t(11;18)(q21;q21) Positive Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Treated With Chemotherapy or Rituximab. <i>Journal of Clinical Oncology</i> , 2005, 23, 7361-7362.	0.8	23
38	Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease. <i>Gut</i> , 2007, 56, 1169-1170.	6.1	23
39	Modulation of <i>JAK2 V617F</i> allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients. <i>British Journal of Haematology</i> , 2011, 152, 413-419.	1.2	23
40	MicroRNAs 142-3p, miR-155 and miR-203 Are Deregulated in Gastric MALT Lymphomas Compared to Chronic Gastritis. <i>Cancer Genomics and Proteomics</i> , 2017, 14, 75-82.	1.0	23
41	Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14. <i>PLoS ONE</i> , 2015, 10, e0123978.	1.1	21
42	RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group. <i>Annals of Hematology</i> , 2020, 99, 799-808.	0.8	21
43	New chromosomal alterations in a series of 23 splenic marginal zone lymphoma patients revealed by Spectral Karyotyping (SKY). <i>Leukemia Research</i> , 2008, 32, 727-736.	0.4	20
44	Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma. <i>Leukemia Research</i> , 2011, 35, 358-362.	0.4	19
45	LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2017, 41, 877-886.	2.1	19
46	Granulomatous Dermatitis with Enlarged Histiocytes: A Characteristic Pattern of Granulocyte Colony-Stimulating Factor. <i>Dermatology</i> , 2006, 212, 188-193.	0.9	17
47	Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study. <i>European Journal of Cancer Care</i> , 2013, 22, 513-521.	0.7	17
48	Progressive Painless Swelling of Glans Penis: Uncommon Clinical Manifestation of Systemic Non-Hodgkin's Lymphoma. <i>Urology</i> , 2009, 73, 929.e3-929.e5.	0.5	16
49	Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1-14.	0.6	16
50	Gastric MALT lymphoma and <i>Helicobacter pylori</i> . <i>Medicina Clínica (English Edition)</i> , 2019, 152, 65-71.	0.1	15
51	Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification. <i>European Journal of Haematology</i> , 2019, 102, 509-515.	1.1	15
52	Recent Advances in the Genetic of MALT Lymphomas. <i>Cancers</i> , 2022, 14, 176.	1.7	15
53	Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series. <i>Leukemia and Lymphoma</i> , 2012, 53, 812-819.	0.6	14
54	Impact of prior rituximab on outcomes of autologous stem cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study. <i>British Journal of Haematology</i> , 2014, 164, 668-674.	1.2	14

#	ARTICLE	IF	CITATIONS
55	Circulating cell-free DNA improves the molecular characterisation of Philadelphia-negative myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2021, 192, 300-309.	1.2	13
56	Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
57	Persistent monoclonality after histological remission in gastric mucosa-associated lymphoid tissue lymphoma treated with chemotherapy and/or surgery: Influence of t(11;18)(q21;q21). <i>Leukemia and Lymphoma</i> , 2008, 49, 1516-1522.	0.6	12
58	Successful dexrazoxane treatment of a potentially severe extravasation of concentrated doxorubicin. <i>Anti-Cancer Drugs</i> , 2010, 21, 790-794.	0.7	12
59	Indolent course as presentation in T-prolymphocytic leukaemia. <i>British Journal of Haematology</i> , 1999, 105, 840-840.	1.2	11
60	A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma. <i>Acta Oncologica</i> , 2015, 54, 933-938.	0.8	11
61	Monoclonal cryoglobulinemia: The first manifestation of gastric marginal B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). <i>Leukemia Research</i> , 2006, 30, 1465-1466.	0.4	10
62	Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone±rituximab chemotherapy: results from an observational study. <i>Leukemia and Lymphoma</i> , 2011, 52, 796-803.	0.6	10
63	Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells. <i>Leukemia and Lymphoma</i> , 2016, 57, 692-699.	0.6	10
64	Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients. <i>Annals of Hematology</i> , 2021, 100, 1023-1029.	0.8	10
65	Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03). <i>Leukemia and Lymphoma</i> , 2011, 52, 409-416.	0.6	9
66	Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain. <i>Leukemia Research</i> , 2012, 36, 709-714.	0.4	9
67	Genetic Characterization and Clinical Features of Helicobacter pylori Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Cancers</i> , 2021, 13, 2993.	1.7	9
68	Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 465-477.	1.0	7
69	Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial. <i>Annals of Hematology</i> , 2017, 96, 639-646.	0.8	7
70	Foamy Histiocyte-Like Hepatocellular Carcinoma (HCC): A New Variant of HCC?. <i>Annals of Hepatology</i> , 2017, 16, 304-307.	0.6	7
71	Differential prognostic impact of GELTAMO±IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm. <i>British Journal of Haematology</i> , 2018, 182, 534-541.	1.2	7
72	Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide. <i>Leukemia and Lymphoma</i> , 2009, 50, 1283-1289.	0.6	6

#	ARTICLE	IF	CITATIONS
73	Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia. <i>Medical Oncology</i> , 2015, 32, 236.	1.2	6
74	Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients. <i>Acta Haematologica</i> , 2016, 136, 76-84.	0.7	6
75	Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity. <i>Blood Advances</i> , 2022, 6, 82-86.	2.5	6
76	Molecular and cytogenetic characterization of myelodysplastic syndromes in cell-free DNA. <i>Blood Advances</i> , 2022, 6, 3178-3188.	2.5	6
77	Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma. <i>Diagnostics</i> , 2022, 12, 1575.	1.3	6
78	Absence of mutations of the histone methyltransferase gene EZH2 in splenic b-cell marginal zone lymphoma. <i>Leukemia Research</i> , 2011, 35, e23-e24.	0.4	5
79	Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2012, 53, 982-984.	0.6	5
80	A new modified prophylactic scheme against liposomal cytarabine-induced arachnoiditis in adult patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 892-893.	0.6	5
81	Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas. <i>Cancers</i> , 2020, 12, 884.	1.7	5
82	Bendamustine-containing immunochemotherapy is active in transformed follicular lymphoma with overexpression of p53. <i>Leukemia and Lymphoma</i> , 2009, 50, 455-456.	0.6	4
83	Blastic Plasmacytoid Dendritic Cell Neoplasm Associated with Dystrophic Xanthomatosis after Chemotherapy. <i>Acta Dermato-Venereologica</i> , 2017, 97, 293-294.	0.6	4
84	Hypopituitarism associated with mycotic aneurysm of the cavernous carotid artery in a renal transplant recipient. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3299-3300.	0.4	3
85	Rituximab subcutaneous in B-cell non-Hodgkin lymphoma: clinical experience in a single center. <i>Leukemia and Lymphoma</i> , 2018, 59, 1019-1021.	0.6	3
86	Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial. <i>Cancer Medicine</i> , 2019, 8, 6955-6966.	1.3	3
87	Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era. <i>European Journal of Haematology</i> , 2020, 104, 400-408.	1.1	3
88	Langerhans cell histiocytosis mimicking relapse in a patient with follicular lymphoma. <i>Annals of Hematology</i> , 2008, 87, 675-676.	0.8	2
89	Lenalidomide-induced paronychia. <i>Journal of Dermatology</i> , 2013, 40, 303-304.	0.6	2
90	Usefulness of second rituximab maintenance after relapse in patients with follicular and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2384-2386.	0.6	2

#	ARTICLE	IF	CITATIONS
91	Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma. <i>European Journal of Haematology</i> , 2016, 96, 532-540.	1.1	2
92	Thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma concurrently diagnosed with a diffuse large B-cell lymphoma localized in the neck. <i>Leukemia and Lymphoma</i> , 2007, 48, 425-427.	0.6	1
93	Prognostic impact of anthracyclines in the treatment of aggressive lymphoma in patients over 70 years. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 544-547.	0.1	1
94	Lack of expression of LMO2 clone SP51 identifies MYC rearrangements in aggressive large B-cell lymphomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, , 1.	1.4	1
95	Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia study. <i>BMC Health Services Research</i> , 2021, 21, 320.	0.9	1
96	T cell lymphoblastic lymphoma with uncommon CD20 expression. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 234-235.	0.7	1
97	Evaluation of routine CT scans in the follow-up of diffuse large B-cell lymphomas. <i>Hematology</i> , 2021, 26, 709-715.	0.7	0
98	IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice. <i>International Journal of Hematology</i> , 2022, , .	0.7	0